AU2021297172B2 - Administration of CEBPβ antagonist and methods of use - Google Patents

Administration of CEBPβ antagonist and methods of use Download PDF

Info

Publication number
AU2021297172B2
AU2021297172B2 AU2021297172A AU2021297172A AU2021297172B2 AU 2021297172 B2 AU2021297172 B2 AU 2021297172B2 AU 2021297172 A AU2021297172 A AU 2021297172A AU 2021297172 A AU2021297172 A AU 2021297172A AU 2021297172 B2 AU2021297172 B2 AU 2021297172B2
Authority
AU
Australia
Prior art keywords
patient
administered
stio
administration
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021297172A
Other languages
English (en)
Other versions
AU2021297172A1 (en
Inventor
Alice Susannah BEXON
Barry Jay Kappel
Gene Merutka
Robert E. Michel
Jimmy Andrew Rotolo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sapience Therapeutics Inc
Original Assignee
Sapience Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sapience Therapeutics Inc filed Critical Sapience Therapeutics Inc
Publication of AU2021297172A1 publication Critical patent/AU2021297172A1/en
Application granted granted Critical
Publication of AU2021297172B2 publication Critical patent/AU2021297172B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021297172A 2020-06-21 2021-06-21 Administration of CEBPβ antagonist and methods of use Active AU2021297172B2 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202063041990P 2020-06-21 2020-06-21
US202063041989P 2020-06-21 2020-06-21
US202063041986P 2020-06-21 2020-06-21
US202063041988P 2020-06-21 2020-06-21
US202063041991P 2020-06-21 2020-06-21
US63/041,988 2020-06-21
US63/041,991 2020-06-21
US63/041,986 2020-06-21
US63/041,989 2020-06-21
US63/041,990 2020-06-21
US202163172560P 2021-04-08 2021-04-08
US63/172,560 2021-04-08
PCT/US2021/038264 WO2021262604A2 (en) 2020-06-21 2021-06-21 Administration of cebp-beta antagonist and methods of use

Publications (2)

Publication Number Publication Date
AU2021297172A1 AU2021297172A1 (en) 2023-01-19
AU2021297172B2 true AU2021297172B2 (en) 2025-01-30

Family

ID=79281738

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021297172A Active AU2021297172B2 (en) 2020-06-21 2021-06-21 Administration of CEBPβ antagonist and methods of use

Country Status (14)

Country Link
US (1) US20230218717A1 (https=)
EP (1) EP4168033B1 (https=)
JP (1) JP2023531683A (https=)
KR (1) KR20230027054A (https=)
CN (1) CN115768458A (https=)
AU (1) AU2021297172B2 (https=)
BR (1) BR112022025880A2 (https=)
CA (1) CA3180559A1 (https=)
FI (1) FI4168033T3 (https=)
IL (1) IL299104A (https=)
MX (1) MX2022016478A (https=)
NZ (1) NZ795026A (https=)
PT (1) PT4168033T (https=)
WO (1) WO2021262604A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025532391A (ja) * 2022-10-07 2025-09-29 サピエンス・セラピューティクス・インコーポレーテッド Ｃ／ｅｂｐ－ベータアンタゴニスト及び免疫調節剤の使用
WO2024216238A2 (en) * 2023-04-13 2024-10-17 Sapience Therapeutics, Inc. Use of beta-catenin antagonist and immunomodulator
AU2024252321A1 (en) * 2023-04-13 2025-10-16 Sapience Therapeutics, Inc. Administration of a beta-catenin antagonist and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516669A (ja) * 2013-02-22 2016-06-09 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 転写因子ａｔｆ５の阻害により腫瘍細胞を阻害するための組成物および方法
US10899834B2 (en) * 2015-04-16 2021-01-26 H. Lundbeck A/S Anti-PACAP antibodies
WO2018152446A2 (en) * 2017-02-20 2018-08-23 Sapience Therapeutics, Inc. Cell-penetrating atf5 polypeptides and uses thereof
WO2019136125A1 (en) * 2018-01-03 2019-07-11 Sapience Therapeutics, Inc. Atf5 peptide variants and uses thereof
WO2020033555A2 (en) * 2018-08-08 2020-02-13 The Trustees Of Columbia University In The City Of New York Dominant negative cebpb and cebpd proteins and methods of use for decreasing viability of neoplastic cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Record History | ver. 1: 2020-07-15 | NCT04478279 | ClinicalTrials.gov", 15 July 2020 (2020-07-15), XP093126427, Retrieved from the Internet [retrieved on 20240201] *
ROTOLO JIM A ET AL: 1 April 2019 (2019-04-01), XP093126423, Retrieved from the Internet <URL:https://sapiencetherapeutics.com/wp-content/uploads/2022/12/Sapience-Therapeutics-2019-AACR-poster.pdf> [retrieved on 20240201] *
SAPIENCE THERAPEUTICS: 7 May 2020 (2020-05-07), Retrieved from the Internet <URL:https://sapiencetherapeutics.com/wp-content/uploads/2023/01/2020-05-07_Sapience_Therapeutics_Receives_United_Kingdom_16.pdf> [retrieved on 20240201] *

Also Published As

Publication number Publication date
WO2021262604A3 (en) 2022-02-17
CN115768458A (zh) 2023-03-07
KR20230027054A (ko) 2023-02-27
FI4168033T3 (fi) 2026-04-07
JP2023531683A (ja) 2023-07-25
BR112022025880A2 (pt) 2023-01-10
EP4168033B1 (en) 2026-02-25
US20230218717A1 (en) 2023-07-13
EP4168033A2 (en) 2023-04-26
AU2021297172A1 (en) 2023-01-19
CA3180559A1 (en) 2021-12-30
EP4168033A4 (en) 2024-06-19
IL299104A (en) 2023-02-01
NZ795026A (en) 2026-03-27
PT4168033T (pt) 2026-03-24
MX2022016478A (es) 2023-02-01
WO2021262604A2 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
JP6776380B2 (ja) 癌モデル及び関連方法
AU2021297172B2 (en) Administration of CEBPβ antagonist and methods of use
CA2759129C (en) Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
JP6351597B2 (ja) 非転移性去勢抵抗性前立腺癌の治療のための抗アンドロゲン剤
US12528846B2 (en) BH4 stabilized peptides and uses thereof
JP2023531683A5 (https=)
WO2014065341A1 (ja) 筋萎縮性側索硬化症治療剤
IL323919A (en) Administration of a beta-catenin antagonist and methods of use
US12558400B2 (en) Method of treatment of soft tissue sarcoma with a peptide comrpising a PCNA interacting motif
US20240358701A1 (en) Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
WO2025110250A1 (ja) 改変ｍｆｇ－ｅ８タンパク質
EP4694912A2 (en) Use of beta-catenin antagonist and immunomodulator
WO2024077297A2 (en) Use of c/ebp-beta antagonist and immunomodulator
HK40022745A (en) Nr4a1 ligands, pharmaceutical compositions, and related methods of use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)